Generated by AI
Outlook Therapeutics, Inc. is a biopharmaceutical company focused on developing and commercializing ophthalmic medicines for retinal diseases. Its principal product, LYTENAVA, is an ophthalmic formulation of bevacizumab designed for use in retinal indications, including wet age-related macular degeneration, diabetic macular edema, and branch retinal vein occlusion. The company’s activities span clinical development, regulatory operations, manufacturing coordination, and commercialization of specialized eye-care therapies. Outlook Therapeutics serves the ophthalmology and retinal-care markets, addressing conditions that can impair vision and require ongoing medical management. Its product platform is centered on monoclonal antibody treatment delivered specifically for ophthalmic use, supporting applications across retinal disease care. Based in Iselin, New Jersey, Outlook Therapeutics, Inc. occupies a specialized role within the biopharmaceutical sector by concentrating its operations on vision-related disorders and therapies intended for administration by eye-care professionals.
Website111 S. Wood Avenue
Iselin, NJ, 08830
United States
The latest articles about OTLK.
Application represents an important step in supporting reimbursement Company remains on track for U.S. commercial launch of LYTENAVA before year-end 2026 ISELIN, N.J., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on the development and commercialization of LYTENAVA™ (bevacizumab-vikg, bevacizumab gamma) for the treatment of retinal diseases, today announced that it has submitted an application to the Centers for Medicare & Medic
Summary of Nov 19's posts. Generated by AI.
Summary of Nov 18's posts. Generated by AI.
Summary of Aug 14's posts. Generated by AI.
Summary of Nov 11's posts. Generated by AI.
Investors talking about OTLK also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.